Moderna Inc (NASDAQ: MRNA) kicked off on Friday, down -3.11% from the previous trading day, before settling in for the closing price of $32.12. Over the past 52 weeks, MRNA has traded in a range of $29.25-$170.47.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 662.63% over the past five years. While this was happening, its average annual earnings per share was recorded -9.79%. With a float of $341.66 million, this company’s outstanding shares have now reached $386.00 million.
Let’s look at the performance matrix of the company that is accounted for 5800 employees. In terms of profitability, gross margin is 52.28%, operating margin of -122.17%, and the pretax margin is -111.71%.
Moderna Inc (MRNA) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Moderna Inc is 11.44%, while institutional ownership is 70.75%. The most recent insider transaction that took place on Mar 03 ’25, was worth 5,004,318. In this transaction Chief Executive Officer of this company bought 160,314 shares at a rate of $31.22, taking the stock ownership to the 9,210,686 shares. Before that another transaction happened on Mar 03 ’25, when Company’s Director bought 31,620 for $31.76, making the entire transaction worth $1,004,251. This insider now owns 312,027 shares in total.
Moderna Inc (MRNA) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -3.08 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -9.79% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 14.34% during the next five years compared to -42.94% drop over the previous five years of trading.
Moderna Inc (NASDAQ: MRNA) Trading Performance Indicators
Take a look at Moderna Inc’s (MRNA) current performance indicators. Last quarter, stock had a quick ratio of 3.62. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.71.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -9.28, a number that is poised to hit -3.08 in the next quarter and is forecasted to reach -7.79 in one year’s time.
Technical Analysis of Moderna Inc (MRNA)
Moderna Inc (NASDAQ: MRNA) saw its 5-day average volume 7.46 million, a negative change from its year-to-date volume of 11.5 million. As of the previous 9 days, the stock’s Stochastic %D was 9.57%. Additionally, its Average True Range was 2.09.
During the past 100 days, Moderna Inc’s (MRNA) raw stochastic average was set at 6.81%, which indicates a significant increase from 1.41% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 51.16% in the past 14 days, which was lower than the 77.97% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $34.74, while its 200-day Moving Average is $63.96. Nevertheless, the first resistance level for the watch stands at $32.07 in the near term. At $33.03, the stock is likely to face the second major resistance level. The third major resistance level sits at $33.55. If the price goes on to break the first support level at $30.59, it is likely to go to the next support level at $30.07. The third support level lies at $29.11 if the price breaches the second support level.
Moderna Inc (NASDAQ: MRNA) Key Stats
The company with the Market Capitalisation of 12.01 billion has total of 386,623K Shares Outstanding. Its annual sales at the moment are 3,236 M in contrast with the sum of -3,561 M annual income. Company’s last quarter sales were recorded 966,000 K and last quarter income was -1,120 M.
